二甲双胍抗肿瘤机制的研究进展advances of the anti-tumor - 药学学报.pdfVIP

12 10 药学学报 Acta Pharmaceutica Sinica 20 15, 50 ( 10): 1210 1216 甲双胍抗肿瘤机制的研究进展 薛朝军, 刘克辛* (大连医科大学药学院, 辽宁 大连 116044) 摘要: 二甲双胍在治疗高血糖与高胰岛素血症方面表现出的有效性、安全性和经济性, 使其成为临床上2 型 糖尿病患者的首选治疗药物。大量的流行病学调查表明, 糖尿病不仅与血管病变的发展有关, 而且与多种恶性肿 瘤的发生密切相关。同时, 流行病学与临床观察显示二甲双胍降低多种肿瘤的发病率, 改善合并2 型糖尿病的肿 瘤患者的预后并能提高生存率。此外, 二甲双胍已经作为抗肿瘤药物应用于临床试验中。因此, 二甲双胍有望成 为一个新的肿瘤治疗药物或辅助抗肿瘤药物。本文对二甲双胍抗肿瘤的分子机制进行综述。 关键词: 2 型糖尿病; 二甲双胍; 单磷酸腺苷依赖的蛋白激酶; 雷帕霉素靶蛋白; 胰岛素; 胰岛素样生长因 子-1; 多药耐药 中图分类号: R963 文献标识码: A 文章编号: 0513-4870 (20 15) 10- 1210-07 Advances of the anti-tumor research of metformin * XUE Chao-j un, LIU Ke-xin (College of Pharmacy, Dalian Medical University, Dalian 116044, China ) Abstract : Metformin is the most commonly prescribed drug for type 2 diabetes mellitus as it is inexpensive, safe, and efficient in ameliorating hyperglycemia and hyperinsulinemia. Numerous epidemiological studies indicate that diabetic population is not only at increased risk of cardiovascular complications, but also at substantially higher risk of many forms of malignancies. Meanwhile, epidemiological and clinical observation studies have shown that metformin use reduces risk of cancer in patients with type 2 diabetes mellitus and improves prognosis and survival rate of the cancer patients. Furthermore, metformin has been used for cancer therapy in clinical trials. Thus, metformin is emerging as a new cancer therapy or adj uvant anticancer drugs. This review summari